Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 43Magnetic Resonance Spectroscopy 39Specimen Handling 29Radiotherapy 19Radiation 16Bevacizumab 14Biopsy 13Nivolumab 12Radiosurgery 11X-Rays 9Cyclophosphamide 9Carboplatin 8Nuclear Medicine Department, Hospital 7Irinotecan 7Ipilimumab 6Cisplatin 6AZD 6244 6Vincristine 5Topotecan 5Phantoms, Imaging 5Lomustine 5Etoposide 5CTLA-4 Antigen 5ulixertinib 4trametinib 4pembrolizumab 4olaparib 4erdafitinib 4dinutuximab 4Surveys and Questionnaires 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
vocimagene amiretrorepvec × CNS × 30 days × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡